Are Hematologic Patients Trojan Horse for COVID-19?

Area of Science:

• Infectious Diseases
• Hematology
• Public Health

Background:

• Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, remains a global health concern.
• Patients with hematologic diseases (HD) may have different clinical outcomes and viral shedding patterns compared to the general population.

Purpose of the Study:

• To compare SARS-CoV-2 viral shedding time between patients with hematologic diseases (HD) and a control group.
• To analyze differences in COVID-19 severity, intensive care unit (ICU) needs, and mortality rates between these groups.

Main Methods:

• A retrospective study involving 110 patients (55 with HD, 55 controls) diagnosed with COVID-19.
• Comparison of viral shedding duration, disease severity, ICU admission, and mortality between the HD group and the control group.

Main Results:

• Median viral shedding time was significantly longer in hospitalized HD patients (24 days) versus controls (12 days) (p<0.01).
• Outpatient HD patients also showed longer shedding (20 days) compared to controls (10 days) (p=0.02).
• Severe-to-critical COVID-19 was more frequent in the HD group (47.2%) than controls (25.4%) (p=0.017), with a higher mortality rate (43.6% in HD vs. 1.8% in controls).

Conclusions:

• Hematologic disease patients experience significantly prolonged SARS-CoV-2 viral shedding.
• Longer-term isolation protocols may be necessary for COVID-19 patients with hematologic conditions.
• Hematologic diseases are associated with increased COVID-19 severity and mortality.